Loading
Piperacillin + Tazobactam / Infection / Acute Kidney Injury · Phase 4 Trial
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 4 safety trial comparing piperacillin/tazobactam and meropenem in hospitalized patients with serious infections. The study is actively recruiting and will measure serum cystatin C at 7 days as the primary endpoint. No results are yet available in this registry record.
Phase 4, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Infection, Acute Kidney Injury, Sepsis; age from 18 Years. Intervention: Piperacillin/tazobactam; Meropenem. Compared with: Meropenem. n = 852. 3 sites: United States.
This is a planned Phase 4 safety trial comparing piperacillin/tazobactam and meropenem in hospitalized patients with serious infections. The study is actively recruiting and will measure serum cystatin C at 7 days as the primary endpoint. No results are yet available in this registry record.
No efficacy or safety results are reported in this registry record; the study is still recruiting Secondary outcomes and clinical endpoints (mortality, clinical cure, adverse events) not stated in this summary
The source did not state who this applies to in practice.
This is a recruiting Phase 4 interventional trial with no results posted; the registry record describes only the planned design and safety endpoints, not outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07556107). This is a study registration, not published results. Lead sponsor: Bassett Healthcare. Recruitment status: RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 852 participants (ESTIMATED). Conditions: Infection, Acute Kidney Injury, Sepsis. Interventions: DRUG: Piperacillin + Tazobactam; DRUG: meropenem. Primary outcome measures: Serum cystatin C (Scys) , 7 days. Brief summary: The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.